



# PROTEKT NEWSLETTER

ISSUE 1

DECEMBER 2015

Welcome to the first PROteKT newsletter. On behalf of Chief Investigators Professor Sir Munir Pirmohamad and Professor Rosalind Smyth we would like to thank you all for all your hard work and contribution to the PROteKT trial.

## Brief summary of PROteKT

**PROteKT** is a phase IIa, multicentre randomised controlled, open label trial of rosuvastatin in children with cystic fibrosis (CF) receiving clinically treatment with intravenous (IV) tobramycin.

Patients will be randomised equally to receive rosuvastatin 10mg daily (treatment arm) or no intervention (control arm).

### SPECIAL POINTS OF INTEREST:

#### PAGE 1

- RECRUITMENT UPDATE
- SPECIAL PRIZE TO BE WON!!!

#### PAGE 2

- SITES OPEN TO RECRUITMENT
- SITES IN SET-UP
- WHAT'S NEW?
- CONVERSATION WALL

## 1st patient recruited @ GOSH

**SPECIAL PRIZE TO BE WON!!**

Congratulations to Dr Helen Spencer and team at Great Ormond Street Hospital for recruiting the first patient into the PROteKT trial. A lovely bottle of champagne was awarded to the team.



Left-right: Philippa Wiltshire, Evelyn Howley

*The first site to recruit patients in three consecutive months will win a SPECIAL PRIZE!!!*



## RECRUITMENT UPDATE



Site	No. of patients randomised
Great Ormond Street Hospital	5
Alder Hey Children's Hospital	2
Bristol Hospital for Children	2
Kings College Hospital	2
Nottingham Children's Hospital	2
Sheffield Children's Hospital	2
Leicester Royal Infirmary	1
University Hospital of North Midlands	1
<b>TOTAL</b>	<b>17</b>



*Of recruitment target reached so far. We're nearly half way there. Keep up the good work!!!*

**PROteKT poster\_leaflets**– this has been designed to promote the PROteKT trial at your centre. The poster\_leaflet can be given to parents, advertised in waiting rooms or included with the information sheet sent to parents. It will also be uploaded to the PROteKT trial website.

**PROteKT certificates (for younger and older children)**- these can be given to participants at the end of their treatment to say thank you for participating in the PROteKT trial.

Both documents are currently pending ethics approval.



To help us reach our recruitment target of **50 patients by June 2016** we are still looking for new sites. If you know any sites that may be interested in opening PROteKT please ask them to email: [protekt\\_trial@ucl.ac.uk](mailto:protekt_trial@ucl.ac.uk)

**THANK YOU TO THE TEAM AT NORTH MIDLANDS AND BRISTOL FOR SUGGESTING THE ABOVE.**

## Meet our Principal Investigators

Site	PI	Date opened
Alder Hey Children's Hospital	Dr Kevin Southern	May 2015
Bristol Hospital for Children	Dr Simon Langton- Hewer	May 2015
Great Ormond Street Hospital	Dr Helen Spencer	May 2015
King's College Hospital	Dr Gary Ruiz	May 2015
Nottingham Children's Hospital	Prof Alan Smyth	May 2015
Sheffield Children's Hospital	Dr Sonal Kansra	May 2015
Leicester Royal Infirmary	Dr Erol Gaillard	November 2015
University Hospital of North Midlands	Dr Francis Gilchrist	November 2015
Brighton and Sussex University Hospitals NHS Foundation Trust	Dr Paul Seddon	In set-up

### Conversation Wall

If you have a question or comment, please email [protekt\\_trial@ucl.ac.uk](mailto:protekt_trial@ucl.ac.uk) and if appropriate we will print the question and answer in the next newsletter.

**Q: If randomised to receive Rosuvastatin (treatment arm) what is the duration of treatment?**

**A:** Treatment with rosuvastatin will continue for the full duration of the course of IV tobramycin (usually 14 days). If IV tobramycin course is shorter or longer than 14 days, rosuvastatin should be discontinued after the final dose of IV tobramycin has been given.



### CONTACT DETAILS

Sawretse (Rexy) Leslie  
PROteKT Trial manager  
Comprehensive Clinical Trials Unit at UCL  
Gower Street | London, WC1E 6BT

Tel: 02076790939 Email: [protekt\\_trial@ucl.ac.uk](mailto:protekt_trial@ucl.ac.uk) Website: <http://www.protekt-trial.org.uk/>